BRIDGEWATER, N.J., Jan. 9, 2020 /PRNewswire/ -- Insmed
Incorporated (Nasdaq: INSM), a global biopharmaceutical company on
a mission to transform the lives of patients with serious and rare
diseases, today announced that Will Lewis, Chairman and Chief
Executive Officer of Insmed, will present at the 38th
Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2020 at 9:00 a.m. PT.
The presentation will be webcast live and can be accessed by
visiting the investor relations section of the company's website at
www.insmed.com. The webcast will be archived for a period of 30
days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is ARIKAYCE®
(amikacin liposome inhalation suspension), which is approved in
the United States for the
treatment of Mycobacterium avium complex (MAC) lung disease
as part of a combination antibacterial drug regimen for adult
patients with limited or no alternative treatment options. MAC lung
disease is a chronic, debilitating condition that can cause severe
and permanent lung damage. Insmed's earlier-stage clinical pipeline
includes INS1007, a novel oral reversible inhibitor of dipeptidyl
peptidase 1 with therapeutic potential in non-cystic fibrosis
bronchiectasis and other inflammatory diseases, and INS1009, an
inhaled formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more information,
visit www.insmed.com.
Contact:
Blaine Davis
Head of Investor Relations and Corporate Communications
Insmed Incorporated
(732) 487-7310
blaine.davis@insmed.com
View original
content:http://www.prnewswire.com/news-releases/insmed-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-300983751.html
SOURCE Insmed Incorporated